Phase 3 Study of Sofosbuvir and Ribavirin

Number of Participants Who Experienced Adverse Events (AEs) and Graded Laboratory Abnormalities

Time frame: Up to 24 weeks plus 30 days following the last dose of study drug

Percentage of Participants With Sustained Virologic Response 24 Weeks After Stopping All Study Drugs (SVR24)

SVR24 was defined as HCV RNA \< LLOQ 24 weeks after study drug cessation.

Time frame: Post-treatment Week 24

Percentage of Participants With HCV RNA < LLOQ on Treatment

Time frame: Up to 12 Weeks

Change From Baseline in HCV RNA

Time frame: Baseline to Week 12

Percentage of Participants With Virologic Failure During Treatment

Virologic failure was defined as either * Viral breakthrough: HCV RNA ≥ 25 IU/mL after having previously had HCV RNA \< 25 IU/mL while on treatment, confirmed with 2 consecutive values or last available measurement * Viral rebound: \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment, confirmed with 2 consecutive values or last available measurement * Non-response: HCV RNA persistently ≥ 25 IU/ml while on treatment (through Week 12)

Time frame: Baseline up to Week 24

Percentage of Participants With Viral Relapse Following Treatment

Viral relapse was defined as HCV RNA ≥ 25 IU/mL in post-treatment after having achieved \< LLOQ at last on-treatment measurement, confirmed with 2 consecutive values or last available measurement.